Trial · NCT03048422
Outcomes25
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 25
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Mothers With HIV-1 RNA Viral Load Less Than 200 Copies/mL at Delivery | Delivery | Women who had plasma HIV-1 RNA viral load data available at delivery | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Mother-infant Pairs With an Adverse Pregnancy Outcome | Delivery | Mother-infant pairs with pregnancy outcome evaluated on study. | percentage of mother-infant pairs | NUMBER |
| PRIMARY | Cumulative Probability of Women Experiencing Grade 3 or Higher Adverse Event | From randomization up to 74 weeks | Enrolled women. | Cumulative probability per 100 persons | NUMBER |
| PRIMARY | Cumulative Probability of Infants Experiencing Grade 3 or Higher Adverse Event | From birth through Week 50 postpartum | Live born infants | Cumulative probability per 100 persons | NUMBER |
| SECONDARY | Percentage of Mothers With HIV-1 RNA Less Than 50 Copies/mL at Delivery Measured at Central Laboratory | Delivery | Women with viral load data available from central laboratory | percentage of participants | NUMBER |
| SECONDARY | Percentage of Mothers With HIV-1 RNA Less Than 200 Copies/mL at 50 Weeks Postpartum | 50 weeks postpartum | Women with viral load data available. | percentage of participants | NUMBER |
| SECONDARY | Time to First HIV-1 RNA Less Than 200 Copies/mL Through Delivery | Randomization to delivery | Women with viral load data available. | weeks | MEAN |
| SECONDARY | Percentage of Mothers With Virologic Success of HIV-1 RNA Less Than 200 Copies/mL at Delivery Based on FDA Snapshot Algorithm | Delivery | Enrolled women | percentage of participants | NUMBER |
| SECONDARY | Percentage of Mothers With Virologic Success of HIV-1 RNA Less Than 200 Copies/mL at 50 Weeks Postpartum Based on FDA Snapshot Algorithm | 50 weeks postpartum | Enrolled women | percentage of participants | NUMBER |
| SECONDARY | Percentage of Mother-Infant Pairs With an Adverse Pregnancy Outcome | Delivery | Mother-infant pairs with pregnancy outcome evaluated on study | percentage of mother-infant pairs | NUMBER |
| SECONDARY | Cumulative Probability of Women Experiencing Grade 3 or Higher Adverse Event | From randomization up to 74 weeks | Enrolled women. | Cumulative probability per 100 persons | NUMBER |
| SECONDARY | Cumulative Probability of Infants Experiencing Grade 3 or Higher Adverse Event | Birth through Week 50 postpartum | Live born infants | Cumulative probability per 100 persons | NUMBER |
| SECONDARY | Percentage of Mother-infant Pairs With an Adverse Pregnancy Outcome or Major Congenital Anomaly | Delivery through 50 weeks postpartum | Mother-infant pairs with pregnancy outcome evaluated on study. | percentage of mother-infant pairs | NUMBER |
| SECONDARY | Count of Mother-infant Pairs in the Classified Ranked Composite Safety Outcome | Birth through 50 weeks postpartum | Mother-infant pairs with pregnancy outcome evaluated on study. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Cumulative Probability of Infant HIV-infection | Birth through 50 weeks after birth | Live born infants | Cumulative probability per 100 persons | NUMBER |
| SECONDARY | Cumulative Probability of Infant Deaths | Birth through 50 weeks after birth | Live born infants | Cumulative probability per 100 persons | NUMBER |
| SECONDARY | Maternal Change in Creatinine Clearance | Baseline to 50 weeks postpartum | Women with creatinine clearance data. | mL/min | MEAN |
| SECONDARY | Infant Creatinine Clearance | Delivery and 26 weeks postpartum | Live born infants with creatinine clearance data | mL/min | MEAN |
| SECONDARY | Percentage of Mothers With HIV-1 ARV Drug Resistance Mutations at the Time of Maternal Virologic Failure | From 24 weeks after randomization through Week 50 postpartum | All enrolled women | percentage of participants | NUMBER |
| SECONDARY | Count of Infants With HIV-1 Antiretroviral Drug Resistance Mutations at the Time of Infant HIV Diagnosis | From birth through 50 weeks postpartum | Infants who had an HIV diagnosis. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03048422/outcomes